Clinical Trials on Hormone-resistant Prostate Cancer in United Kingdom
Total 7279 results
-
Terence Friedlander, MDJanssen Biotech, Inc.CompletedCastration Resistant Prostate CancerUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedMetastatic Castration-Resistant Prostate CancerBelgium, France, Germany, Spain, United Kingdom
-
Tulane UniversityBlue Earth DiagnosticsCompletedMetastatic Castration-resistant Prostate CancerUnited States
-
Memorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.CompletedMetastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsCompletedCastrate Resistant Prostate Cancer (CRPC)United States
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration-Resistant Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedProstate Cancer | Metastatic Castrate Resistant Prostate CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnMicrosatellite Instability | Hormone-Resistant Prostate Cancer | Castration Levels of TestosteroneUnited States
-
EndocyteTerminatedMetastatic Castration Resistant Prostate CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCelgene CorporationCompletedProstate Cancer | Castration Resistant Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Mayo ClinicActive, not recruitingBreast Cancer | Recurrent Prostate Cancer | Hormone-resistant Prostate CancerUnited States
-
Exosome Diagnostics, Inc.Yale UniversitySuspendedMetastatic Castrate Resistant Prostate CancerUnited States
-
Jodi Layton, MDEMD SeronoTerminatedMetastatic Castration-resistant Prostate CancerUnited States
-
Pellficure Pharmaceuticals, IncTerminatedMetastatic Castration-Resistant Prostate CancerUnited States
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
Astellas Pharma Global Development, Inc.PfizerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate CancerUnited States
-
Janssen Research & Development, LLCCompletedMetastatic Breast Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Belgium, Spain, Germany, Sweden, Australia, United Kingdom
-
Suzhou Kintor Pharmaceutical Inc,CompletedMetastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)United States
-
BayerCompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
AstraZenecaCompletedMetastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.United Kingdom, United States
-
University of Texas Southwestern Medical CenterCompletedmCRPC | Metastatic Castrate-resistant Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Progressive Castration-resistant Prostate CancerUnited States
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.CompletedProstate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
University of Alabama at BirminghamAmgenCompletedPhase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following TreatmentMetastatic Castration-resistant Prostate CancerUnited States
-
Rahul AggarwalSanofiCompletedMetastatic Castration-resistant Prostate CancerUnited States
-
Duke UniversityBayerCompletedPharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate CancerBone Metastatic Castration-Resistant Prostate CancerUnited States
-
Dizal PharmaceuticalsTerminatedMetastatic Castration Resistant Prostate CancerUnited States, Korea, Republic of
-
BayerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
AmgenTerminatedMetastatic Castration-resistant Prostate CancerUnited States, Sweden, Spain, United Kingdom, Australia, Denmark
-
UNC Lineberger Comprehensive Cancer CenterWithdrawnMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Rashmi Verma, MDNational Cancer Institute (NCI)RecruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8United States
-
Zenith EpigeneticsCompletedMetastatic Castration-Resistant Prostate CancerUnited States
-
Gilead SciencesTerminatedMetastatic Castrate-Resistant Prostate CancerUnited States
-
Zenith EpigeneticsCompletedMetastatic Castration-Resistant Prostate CancerUnited States
-
University College London HospitalsCompleted
-
Astellas Pharma Global Development, Inc.Medivation, Inc.TerminatedMetastatic Castration Resistant Prostate CancerUnited States
-
OHSU Knight Cancer InstituteMerck Sharp & Dohme LLC; Oregon Health and Science University; Collins Medical...Active, not recruitingCastration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | PSA Progression | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma Cancer AJCC v8United States
-
ExelixisTerminatedProstatic Neoplasms | Prostate Cancer | Castration Resistant Prostate CancerUnited States
-
Sumitomo Pharma Switzerland GmbHActive, not recruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedCastration Resistant Prostate Cancer | Prostate Carcinoma Metastatic to the BoneUnited States
-
Innocrin PharmaceuticalCompletedCastration-resistant Prostate Cancer | CRPCUnited States
-
Dana-Farber Cancer InstituteMedivation, Inc.CompletedMetastatic Castration-resistant Prostate CancerUnited States
-
BayerActive, not recruitingBone Metastatic Castration-resistant Prostate CancerFrance, Lithuania, Israel, Italy, United Kingdom, Austria
-
Hoffmann-La RocheCompleted
-
Bellicum PharmaceuticalsCompletedCastrate Resistent Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedCastration-Resistant Prostate CancerUnited States, Canada, France, Spain, United Kingdom, Australia, Poland, Germany, Austria, Belgium, Netherlands, Italy, Chile, South Africa, Argentina
-
Athenex, Inc.CompletedBone-Metastatic, Castration-Resistant Prostate CancerUnited States
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
-
University College, LondonKing's College London; Imperial College London; Medical Research Council; Cancer...Completed